Bfsg LLC Invests $63,000 in Bausch Health Companies Inc. (NYSE:BHC)

Bfsg LLC acquired a new position in shares of Bausch Health Companies Inc. (NYSE:BHC) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 7,807 shares of the company’s stock, valued at approximately $63,000.

Several other institutional investors also recently modified their holdings of BHC. Commonwealth Equity Services LLC grew its holdings in shares of Bausch Health Companies by 16.3% during the 3rd quarter. Commonwealth Equity Services LLC now owns 45,699 shares of the company’s stock worth $376,000 after purchasing an additional 6,399 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Bausch Health Companies by 15.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 56,783 shares of the company’s stock valued at $470,000 after buying an additional 7,465 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Bausch Health Companies by 8.1% in the 3rd quarter. Mackenzie Financial Corp now owns 1,231,232 shares of the company’s stock valued at $9,869,000 after buying an additional 92,515 shares in the last quarter. Park Avenue Securities LLC acquired a new stake in Bausch Health Companies in the 3rd quarter valued at $169,000. Finally, TD Asset Management Inc boosted its stake in Bausch Health Companies by 17.5% in the 3rd quarter. TD Asset Management Inc now owns 1,137,247 shares of the company’s stock valued at $9,421,000 after buying an additional 169,531 shares in the last quarter. Institutional investors and hedge funds own 78.65% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on BHC. StockNews.com raised Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th. Jefferies Financial Group decreased their price target on Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Finally, Royal Bank of Canada decreased their price target on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating on the stock in a research note on Tuesday.

Bausch Health Companies Trading Down 0.3 %

Shares of BHC opened at $8.59 on Friday. The stock has a fifty day moving average price of $9.30 and a two-hundred day moving average price of $8.16. Bausch Health Companies Inc. has a 52-week low of $5.57 and a 52-week high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. The business’s revenue for the quarter was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.02 EPS. Analysts expect that Bausch Health Companies Inc. will post 3.95 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.